This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Rosanò, L. Articles by Bagnato, A. Search for Related Content PubMed PubMed Citation Articles by Rosanò, L. Articles by Bagnato, A.

(American Journal of Pathology. 2003;163:753-762.)
© 2003 American Society for Investigative Pathology

Endothelin Receptor Blockade Inhibits Molecular Effectors of Kaposi’s Sarcoma Cell Invasion and Tumor Growth in Vivo

Laura Rosanò^*, Francesca Spinella^*, Valeriana Di Castro^*, Maria Rita Nicotra, Adriana Albini, Pier Giorgio Natali and Anna Bagnato^*

From the Laboratories of Molecular Pathology and Ultrastructure^* and Immunology, Regina Elena Cancer Institute, and the Molecular Biology and Pathology Institute, Consiglio Nazionale delle Ricerche, Rome; and National Institute for Cancer Research, Center of Advanced Biotechnology, Genoa, Italy

Endothelin-1 (ET-1) and its receptors are overexpressed in human Kaposi’s sarcoma lesions. Here we show that in human KS IMM cell line ET-1 increased secretion and activation of matrix-metalloproteinase-2 (MMP-2), -3, -7, -9 and -13, as well as of membrane-type 1-MMP (MT1-MMP). ET-1 and ET-3 also enhanced the expression of tissue inhibitor of MMP-2, essential for MT1-MMP-mediated MMP-2 activation. Combined addition of both ET_B receptor (ET_BR) and ET_AR antagonists completely blocked the ET-1-induced MMP activity. By immunohistochemistry, we observed that ET-1 increased MMP-2 and MT1-MMP expression and their localization at the cell surface. Treatment with both antagonists resulted also in the suppression of ET-1-induced phosphorylation of focal adhesion proteins, FAK and paxillin, which are essentials for cell motility. ET-1 induced a dose-dependent enhancement in KS IMM cell migration and MMP-dependent invasiveness that were inhibited by ET-1 receptor antagonists. The small molecule, A-182086, an orally bioavailable ET_A/BR antagonist, completely inhibited cell proliferation and tumor growth in KS IMM xenografts. These findings demonstrate that ET-1-driven autocrine loop is crucial for enhanced invasiveness of KS IMM cells and promote tumor growth in vivo. Such activities can be blocked by the ET_A/BR antagonists, which may be effective anti-angiogenic and anti-tumor molecules for the treatment of Kaposi’s sarcoma.

This article has been cited by other articles:

				S. Bien, A. Riad, C. A. Ritter, M. Gratz, F. Olshausen, D. Westermann, M. Grube, T. Krieg, S. Ciecholewski, S. B. Felix, et al. The Endothelin Receptor Blocker Bosentan Inhibits Doxorubicin-Induced Cardiomyopathy Cancer Res., November 1, 2007; 67(21): 10428 - 10435. [Abstract] [Full Text] [PDF]

				M J Grimshaw Endothelins and hypoxia-inducible factor in cancer Endocr. Relat. Cancer, June 1, 2007; 14(2): 233 - 244. [Abstract] [Full Text] [PDF]

				L. Speciale, R. Biffi, R. Mancuso, E. Borghi, R. Mazziotti, and P. Ferrante Big Endothelin-1 and Interleukin-6 Modulation in Human Microvascular Endothelial Cells After Human Herpesvirus 8 Infection Exp Biol Med, June 1, 2006; 231(6): 1171 - 1175. [Abstract] [Full Text] [PDF]

				B. J. Dezube, S. E. Krown, J. Y. Lee, K. S. Bauer, and D. M. Aboulafia Randomized Phase II Trial of Matrix Metalloproteinase Inhibitor COL-3 in AIDS-Related Kaposi's Sarcoma: An AIDS Malignancy Consortium Study J. Clin. Oncol., March 20, 2006; 24(9): 1389 - 1394. [Abstract] [Full Text] [PDF]

				A. Bagnato, F. Spinella, and L. Rosano Emerging role of the endothelin axis in ovarian tumor progression Endocr. Relat. Cancer, December 1, 2005; 12(4): 761 - 772. [Abstract] [Full Text] [PDF]